Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATTE: Hypertonic Lactate After Cardiac Arrest
NCT05004610Phase 2Recruiting
- Sponsor
- Erasmus Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lactated ringer's solution in anoxic brain injury (ABI) and ischemia-reperfusion injury (IRI) (2 arms), sponsored by Erasmus Hospital. Primary endpoint: Serum Neuron-Specific Enolase at 48 hours. Started Feb 2025; status: recruiting.
02
Drugs
lactated ringer's solution
03
Conditions
anoxic brain injury (ABI)ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT05004610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004610.